Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective

Wells, 2014, Treatment of venous thromboembolism, JAMA, 311, 717, 10.1001/jama.2014.65 Steinberg, 2014, Anticoagulation in atrial fibrillation, BMJ, 348, g2116, 10.1136/bmj.g2116 Lip, 2015, Stroke prevention in atrial fibrillation: a systematic review, JAMA, 313, 1950, 10.1001/jama.2015.4369 Verheugt, 2015, Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs, Lancet, 386, 303, 10.1016/S0140-6736(15)60245-8 Raschi, 2016, Risk-Benefit profile of direct-Acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies, Drug Saf., 39, 1175, 10.1007/s40264-016-0464-3 Li, 2016, Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials, Eur. J. Epidemiol., 31, 541, 10.1007/s10654-016-0178-y Kirchhof, 2016, Eur. Heart J., 2016 You, 2012, 141, e531S Kearon, 2016, Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report, Chest, 149, 315, 10.1016/j.chest.2015.11.026 Kovacs, 2015, Practical management of anticoagulation in patients with atrial fibrillation, J. Am. Coll. Cardiol., 65, 1340, 10.1016/j.jacc.2015.01.049 Shields, 2015, Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation, J. Intern. Med., 278, 1, 10.1111/joim.12360 Lip, 2016, A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation, J. Intern. Med., 279, 467, 10.1111/joim.12468 Van G, 2016, Tailored treatment strategies: a new approach for modern management of atrial fibrillation, J. Intern. Med., 279, 457, 10.1111/joim.12489 Heidbuchel, 2015, Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation, Europace, 17, 1467, 10.1093/europace/euv309 Lip, 2015, Matching the NOAC to the patient: remember the modifiable bleeding risk factors, J. Am. Coll. Cardiol., 66, 2282, 10.1016/j.jacc.2015.07.086 Raschi, 2016, Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications, Pol. Arch. Med. Wewn, 126, 552 Chan, 2016, Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants, Circ. Res., 118, 1409, 10.1161/CIRCRESAHA.116.306925 Diener, 2016, Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1, Eur. Heart J. Diener, 2016, Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2, Eur. Heart J. Bertoletti, 2017, Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism, Pharmacol. Res., 118, 33, 10.1016/j.phrs.2016.06.023 Salvo, 2017, Pharmacological treatments of cardiovascular diseases: evidence from real-life studies, Pharmacol. Res., 118, 43, 10.1016/j.phrs.2016.08.006 Shea, 2007, Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews, BMC Med. Res. Methodol., 7, 10, 10.1186/1471-2288-7-10 Sardar, 2014, New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials, J. Am. Geriatr. Soc., 62, 857, 10.1111/jgs.12799 Sharma, 2015, Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis, Circulation, 132, 194, 10.1161/CIRCULATIONAHA.114.013267 Sadlon, 2016, Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions, Swiss Med. Wkly, 146, w14356 Abraham, 2015, Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study, BMJ, 350, h1857, 10.1136/bmj.h1857 vgil-Tsadok, 2016, Dabigatran use in elderly patients with atrial fibrillation, Thromb. Haemost., 115, 152, 10.1160/TH15-03-0247 Romanelli, 2016, Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis, Circ. Cardiovasc. Qual. Outcomes, 9, 126, 10.1161/CIRCOUTCOMES.115.002369 Watson, 2015, Guideline on aspects of cancer-related venous thrombosis, Br. J. Haematol., 170, 640, 10.1111/bjh.13556 Khorana, 2010, Venous thromboembolism and prognosis in cancer, Thromb. Res., 125, 490, 10.1016/j.thromres.2009.12.023 Baron, 1998, Venous thromboembolism and cancer, Lancet, 351, 1077, 10.1016/S0140-6736(97)10018-6 Wilts, 2015, Safety of anticoagulant treatment in cancer patients, Expert Opin. Drug Saf., 14, 1227, 10.1517/14740338.2015.1052739 Di Nisio, 2016, Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy, Cochrane Database Syst. Rev., 12, CD008500 Farge, 2013, International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, J. Thromb. Haemost., 11, 56, 10.1111/jth.12070 Zwicker, 2016, A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation, J. Thromb. Haemost., 14, 1736, 10.1111/jth.13387 Weinstock, 2016, Intracranial hemorrhage in cancer patients treated with anticoagulation, Thromb. Res., 140, S60, 10.1016/S0049-3848(16)30100-1 Mandala, 2011, Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines, Ann. Oncol., 22, vi85, 10.1093/annonc/mdr392 Lyman, 2013, Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update, J. Clin. Oncol., 31, 2189, 10.1200/JCO.2013.49.1118 Streiff, 2013, Venous thromboembolic disease, J. Natl. Compr. Canc. Netw., 11, 1402, 10.6004/jnccn.2013.0163 Khorana, 2016, Guidance for the prevention and treatment of cancer-associated venous thromboembolism, J. Thromb. Thrombolysis, 41, 81, 10.1007/s11239-015-1313-4 Levine, 2012, A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer, J. Thromb. Haemost., 10, 807, 10.1111/j.1538-7836.2012.04693.x Lee, 2003, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N. Engl. J. Med., 349, 146, 10.1056/NEJMoa025313 Lee, 2015, Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial, JAMA, 314, 677, 10.1001/jama.2015.9243 Farge, 2016, International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol., 17, e452, 10.1016/S1470-2045(16)30369-2 Carrier, 2014, Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis, Thromb. Res., 134, 1214, 10.1016/j.thromres.2014.09.039 Gomez-Outes, 2014, Vargas-Castrillon E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis, Thromb. Res., 134, 774, 10.1016/j.thromres.2014.06.020 Larsen, 2014, Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes, PLoS One, 9, e114445, 10.1371/journal.pone.0114445 Posch, 2015, Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants, Thromb. Res., 136, 582, 10.1016/j.thromres.2015.07.011 van der Hulle, 2014, Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism, J. Thromb. Haemost., 12, 1116, 10.1111/jth.12605 van Es, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 Vedovati, 2015, Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis, Chest, 147, 475, 10.1378/chest.14-0402 Bott-Kitslaar, 2016, Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry, Am. J. Med., 129, 615, 10.1016/j.amjmed.2015.12.025 Mantha, 2017, Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study, J. Thromb. Thrombolysis, 43, 166, 10.1007/s11239-016-1429-1 Ruff, 2016, Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents, Circulation, 134, 248, 10.1161/CIRCULATIONAHA.116.021831 Salmonson, 2017, Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA), Eur. Heart J. Cardiovasc. Pharmacother., 3, 42, 10.1093/ehjcvp/pvw032 Arobelidze, 2016, New anticoagulants in cancer patient treatments, Anticancer Drugs, 27, 832, 10.1097/CAD.0000000000000404 Fitzgerald, 2016, Drug interactions of direct-acting oral anticoagulants, Drug Saf., 39, 841, 10.1007/s40264-016-0443-8 Narasimha Krishna, 2015, Oral anticoagulants and risk of nephropathy, Drug Saf., 38, 527, 10.1007/s40264-015-0290-z Lau, 2016, Atrial fibrillation and thromboembolism in patients with chronic kidney disease, J. Am. Coll. Cardiol., 68, 1452, 10.1016/j.jacc.2016.06.057 Chan, 2016, Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF, J. Am. Coll. Cardiol., 67, 2888, 10.1016/j.jacc.2016.02.082 Piccini, 2013, Circulation, 127, 224, 10.1161/CIRCULATIONAHA.112.107128 Bautista, 2015, Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure, Clin. Kidney J., 8, 226, 10.1093/ckj/sfv006 Friberg, 2015, Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study, Eur. Heart J., 36, 297, 10.1093/eurheartj/ehu139 Dahal, 2016, Major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies, Chest, 149, 951, 10.1378/chest.15-1719 Li, 2015, Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis, Nutr. Metab. Cardiovasc. Dis., 25, 706, 10.1016/j.numecd.2015.03.013 Raccah, 2016, Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials, Chest, 149, 1516, 10.1016/j.chest.2015.12.029 Nielsen, 2015, Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis, Clin. Res. Cardiol., 104, 418, 10.1007/s00392-014-0797-9 Chan, 2015, Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis, Circulation, 131, 972, 10.1161/CIRCULATIONAHA.114.014113 Chai-Adisaksopha, 2015, Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review, J. Thromb. Haemost., 13, 1790, 10.1111/jth.13117 Stollberger, 2016, Pipe dreams about apixaban for stroke prevention in renal impairment, J. Clin. Pharmacol., 56, 646, 10.1002/jcph.656 Tripodi, 2010, Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged, Intern. Emerg. Med., 5, 7, 10.1007/s11739-009-0302-z Intagliata, 2015, Anticoagulant therapy in patients with cirrhosis, Semin. Thromb. Hemost., 41, 514, 10.1055/s-0035-1550436 Lisman, 2013, Established and new-generation antithrombotic drugs in patients with cirrhosis—possibilities and caveats, J. Hepatol., 59, 358, 10.1016/j.jhep.2013.03.027 Intagliata, 2016, Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation, Dig. Dis. Sci., 61, 1721, 10.1007/s10620-015-4012-2 Intagliata, 2015, Treating thrombosis in cirrhosis patients with new oral agents: ready or not, Hepatology, 61, 738, 10.1002/hep.27225 Martinez, 2014, Treatment of acute portal vein thrombosis by nontraditional anticoagulation, Hepatology, 60, 425, 10.1002/hep.26998 Bates, 2016, Guidance for the treatment and prevention of obstetric-associated venous thromboembolism, J. Thromb. Thrombolysis, 41, 92, 10.1007/s11239-015-1309-0 Cohen, 2016, Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH, J. Thromb. Haemost., 14, 1673, 10.1111/jth.13366 Hoeltzenbein, 2016, Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre, Clin. Res. Cardiol., 105, 117, 10.1007/s00392-015-0893-5 Beyer-Westendorf, 2016, Pregnancy outcome in patients exposed to direct oral anticoagulants − and the challenge of event reporting, Thromb. Haemost., 116, 651, 10.1160/TH16-04-0305 vonVajna, 2016, Current clinical trials on the use of direct oral anticoagulants in the pediatric population, Cardiol. Ther., 5, 19, 10.1007/s40119-015-0054-y Monagle, 2012, 141, e737S Greinacher, 2015, Clinical practice. Heparin-induced thrombocytopenia, N. Engl. J. Med., 373, 252, 10.1056/NEJMcp1411910 Skelley, 2016, Novel oral anticoagulants for heparin-induced thrombocytopenia, J. Thromb. Thrombolysis, 42, 172, 10.1007/s11239-016-1365-0 Dhakal, 2015, New oral anticoagulants for the management of heparin induced thrombocytopenia: a focused literature review, Cardiovasc. Hematol. Agents Med. Chem., 13, 87, 10.2174/187152571302151217124551 Shatzel, 2016, Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia: a systematic review of 54 reported cases, Thromb. Haemost., 116, 397, 10.1160/TH16-02-0101 Keeling, 2012, Guidelines on the investigation and management of antiphospholipid syndrome, Br. J. Haematol., 157, 47, 10.1111/j.1365-2141.2012.09037.x Chighizola, 2014, New oral anticoagulants in thrombotic antiphospholipid syndrome, Lupus, 23, 1279, 10.1177/0961203314540968 Chighizola, 2015, Update on the pathogenesis and treatment of the antiphospholipid syndrome, Curr. Opin. Rheumatol., 27, 476, 10.1097/BOR.0000000000000200 Dufrost, 2016, Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? a systematic review of the literature, Curr. Rheumatol. Rep., 18, 74, 10.1007/s11926-016-0623-7 Cohen, 2016, Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial, Lancet Haematol., 3, e426, 10.1016/S2352-3026(16)30079-5 Pengo, 2016, Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus, 25, 301, 10.1177/0961203315611495 Woller, 2016, Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS), Clin. Appl. Thromb. Hemost, 22, 239, 10.1177/1076029615615960 Ataga, 2015, The trials and hopes for drug development in sickle cell disease, Br. J. Haematol., 170, 768, 10.1111/bjh.13548 Sparkenbaugh, 2014, Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease, Blood, 123, 1747, 10.1182/blood-2013-08-523936 Finazzi, 2016, Direct oral anticoagulants in rare venous thrombosis, Intern. Emerg. Med., 11, 167, 10.1007/s11739-016-1398-6 Ageno, 2016, Guidance for the management of venous thrombosis in unusual sites, J. Thromb. Thrombolysis, 41, 129, 10.1007/s11239-015-1308-1 Beyer-Westendorf, 2017, Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial, Lancet Haematol., 4, e105, 10.1016/S2352-3026(17)30014-5 Plovanich, 2015, Novel oral anticoagulants: what dermatologists need to know, J. Am. Acad. Dermatol., 72, 535, 10.1016/j.jaad.2014.11.013 Kerk, 2013, Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy, Br. J. Dermatol., 168, 898, 10.1111/bjd.12100 Winchester, 2015, Response of livedoid vasculopathy to rivaroxaban, Br. J. Dermatol., 172, 1148, 10.1111/bjd.13428 Weishaupt, 2016, Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial, Lancet Haematol., 3, e72, 10.1016/S2352-3026(15)00251-3 Joseph, 2016, Dabigatran etexilate and reduction in serum apolipoprotein B, Heart, 102, 57, 10.1136/heartjnl-2015-307586 Prisco, 2017, Italian intersociety consensus on DOAC use in internal medicine, Intern. Emerg. Med.